Complement activation correlates with liver necrosis and fibrosis in chronic hepatitis C

Clinical Immunology

Volumn 150, Issue 2, 2014, Pages 149-156

  Vasel, Matthäus ^a,b   Rutz, Renate ^b   Bersch, Claus ^b   Feick, Peter ^b   Singer, Manfred V ^b   Kirschfink, Michael ^b   Nakchbandi, Inaam A ^a,b  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chronic hepatitis C; Complement; Fibronectin; Fibrosis; Inflammation; Stellate cell

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; CHOLINESTERASE; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C3A; FIBRONECTIN; GAMMA GLUTAMYLTRANSFERASE; MESSENGER RNA;

ADULT; ARTICLE; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL CHEMISTRY; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; CORRELATIONAL STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HOSPITAL PATIENT; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INTRAHEPATIC CHOLESTASIS; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION; LIVER NECROSIS; MALE; MIDDLE AGED; NEPHELOMETRY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STELLATE CELL; T LYMPHOCYTE ACTIVATION; VIRUS VIRULENCE;

CHRONIC HEPATITIS C;; COMPLEMENT;; FIBRONECTIN; FIBROSIS;; INFLAMMATION;; STELLATE CELL;;

ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; COMPLEMENT SYSTEM PROTEINS; FEMALE; FIBRONECTINS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NECROSIS; PROGNOSIS;

EID: 84892173378     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.11.014     Document Type: Article

References (33)

1. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., Alter M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 2006, 144(10):705-714. (Epub 2006/05/17).
2. ECDC Technical Report: Hepatitis B and C in the EU Neighbourhood: Prevalence, Burden of Disease and Screening Policies 2010, ECDC, Stockholm.
3. Tarr A.W., Urbanowicz R.A., Ball J.K. The role of humoral innate immunity in hepatitis C virus infection. Viruses 2012, 4(1):1-27. (Epub 2012/02/23).
4. Vasei M., Monabbati A., Alizadeh-Naeeni M., Houshmand S., Azarpira N., Lankarani K.B., et al. Immunoglobulin and complement depositions in the liver of chronic hepatitis patients. Hepatogastroenterology 2008, 55(84):1066-1070. (Epub 2008/08/19).
5. Lee I.N., Chen C.H., Sheu J.C., Lee H.S., Huang G.T., Chen D.S., et al. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics 2006, 6(9):2865-2873. (Epub 2006/04/06).
6. Mazumdar B., Kim H., Meyer K., Bose S.K., Di Bisceglie A.M., Ray R.B., et al. Hepatitis C virus proteins inhibit C3 complement production. J. Virol. 2012, 86(4):2221-2228. (Epub 2011/12/16).
7. Ejaz A., Steinmann E., Banki Z., Anggakusuma, Khalid S., Lengauer S., et al. Specific acquisition of functional CD59 but not CD46 or CD55 by hepatitis C virus. PLoS One 2012, 7(9):e45770.
8. Gangadharan B., Antrobus R., Dwek R.A., Zitzmann N. Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin. Chem. 2007, 53(10):1792-1799. (Epub 2007/08/19).
9. Hillebrandt S., Goos C., Matern S., Lammert F. Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. Gastroenterology 2002, 123(6):2041-2051. (Epub 2002/11/28).
10. Hillebrandt S., Wasmuth H.E., Weiskirchen R., Hellerbrand C., Keppeler H., Werth A., et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat. Genet. 2005, 37(8):835-843. (Epub 2005/07/05).
11. Halangk J., Sarrazin C., Neumann K., Puhl G., Mueller T., Teuber G., et al. Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection. J. Hepatol. 2008, 49(3):339-345. (Epub 2008/07/23).
12. Hackl N.J., Bersch C., Feick P., Antoni C., Franke A., Singer M.V., et al. Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C. Scand. J. Gastroenterol. 2010, 45(3):349-356. (Epub 2009/12/19).
13. Mayer M. Complement and complement fixation. Experimental Immunochemistry 1961, 133-240. Charles C. Thomas, Springfield. E. Kabat, M. Mayer (Eds.).
14. Kotnik V., Luznik-Bufon T., Schneider P.M., Kirschfink M. Molecular, genetic, and functional analysis of homozygous C8 beta-chain deficiency in two siblings. Immunopharmacology 1997, 38(1-2):215-221. (Epub 1998/02/26).
15. Kawelke N., Bentmann A., Hackl N., Hager H.D., Feick P., Geursen A., et al. Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation. J. Bone Miner. Res. 2008, 23(8):1278-1286.
16. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 1995, 22(6):696-699.
17. Group TFMCS Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994, 20(1 Pt 1):15-20.
18. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24(2):289-293.
19. Brunt E.M. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000, 31(1):241-246.
20. Yao Z.Q., Ray S., Eisen-Vandervelde A., Waggoner S., Hahn Y.S. Hepatitis C virus: immunosuppression by complement regulatory pathway. Viral Immunol. 2001, 14(4):277-295. (Epub 2002/01/17).
21. Yao Z.Q., Nguyen D.T., Hiotellis A.I., Hahn Y.S. Hepatitis C virus core protein inhibits human T lymphocyte responses by a complement-dependent regulatory pathway. J. Immunol. 2001, 167(9):5264-5272. (Epub 2001/10/24).
22. Lienesch D.W., Sherman K.E., Metzger A., Shen G.Q. Anti-Clq antibodies in patients with chronic hepatitis C infection. Clin. Exp. Rheumatol. 2006, 24(2):183-185. (Epub 2006/06/10).
23. Saadoun D., Sadallah S., Trendelenburg M., Limal N., Sene D., Piette J.C., et al. Anti-C1q antibodies in hepatitis C virus infection. Clin. Exp. Immunol. 2006, 145(2):308-312. (Epub 2006/08/02).
24. Brown K.S., Keogh M.J., Owsianka A.M., Adair R., Patel A.H., Arnold J.N., et al. Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. Protein Cell 2010, 1(7):664-674. (Epub 2011/01/05).
25. Nomura H., Ogo T., Rikimaru N., Ueno S., Kakuno T., Okamoto O., et al. Hepatitis C virus-related liver damage is related to cold activation of complement. J. Clin. Gastroenterol. 1997, 25(3):529-534. (Epub 1997/12/31).
26. Mollnes T.E., Jokiranta T.S., Truedsson L., Nilsson B., Rodriguez de Cordoba S., Kirschfink M. Complement analysis in the 21st century. Mol. Immunol. 2007, 44(16):3838-3849.
27. Stoermer K.A., Morrison T.E. Complement and viral pathogenesis. Virology 2011, 411(2):362-373. (Epub 2011/02/05).
28. Bedossa P., Carrat F. Liver biopsy: the best, not the gold standard. J. Hepatol. 2009, 50(1):1-3. (Epub 2008/11/20).
29. Bedossa P., Dargere D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38(6):1449-1457.
30. Banerjee A., Mazumdar B., Meyer K., Di Bisceglie A.M., Ray R.B., Ray R. Transcriptional repression of C4 complement by hepatitis C virus proteins. J. Virol. 2011, 85(9):4157-4166. (Epub 2011/02/25).
31. Large M.K., Kittlesen D.J., Hahn Y.S. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J. Immunol. 1999, 162(2):931-938. (Epub 1999/01/23).
32. Kittlesen D.J., Chianese-Bullock K.A., Yao Z.Q., Braciale T.J., Hahn Y.S. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J. Clin. Invest. 2000, 106(10):1239-1249. (Epub 2000/11/22).
33. Cummings K.L., Rosen H.R., Hahn Y.S. Frequency of gC1qR+CD4+ T cells increases during acute hepatitis C virus infection and remains elevated in patients with chronic infection. Clin. Immunol. 2009, 132(3):401-411. (Epub 2009/05/29).